• Publications
  • Influence
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Resistance of medulloblastoma to Smo antagonists can be delayed or prevented by specific drug combinations. An End Run Against Tumor Resistance Cancer cells are as clever as microbes. Mustering theirExpand
  • 473
  • 30
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Disregulated Wnt/β-catenin signaling has been linked to various human diseases, including cancers. Inhibitors of oncogenic Wnt signaling are likely to have a therapeutic effect in cancers. LRP5 andExpand
  • 126
  • 12
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
Multiple therapeutic agonists of death receptor 5 (DR5) have been developed and are under clinical evaluation. Although these agonists demonstrate significant anti-tumor activity in preclinicalExpand
  • 50
  • 6
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.
Despite an improving therapeutic landscape, significant challenges remain in treating the majority of patients with advanced ovarian or renal cancer. We identified the cell-cell adhesion moleculeExpand
  • 17
  • 1
Abstract 4290: The smoothened antagonist NVP-LDE225 targets stroma and cancer stem cells in primary human pancreatic tumor xenografts
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality. Despite surgical intervention and treatment with Gemcitabine, the standard of care, the 5-year survival rateExpand
  • 1
Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program.
3092 Background: LDE225 is a potent and highly selective inhibitor of Smo, a key regulator protein in the Hedgehog (Hh) signaling pathway, which is linked to the pathogenesis of several humanExpand
  • 1
Abstract A41: The preanalytic impact of simulated ischemia on PI3K biomarkers
Introduction: Pharmacodynamic (PD) measurements in patient tissues following administration of cancer drugs may be used to determine a drug9s activity and calculate dosing schedules. BiomarkerExpand
  • 1
Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer
In an attempt to mine tumor versus normal mRNA expression datasets for novel tumor antigens, we identified the Cadherin-6 (CDH6) gene as frequently overexpressed in ovarian and renal cancers, whileExpand
Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial
The Cadherin-6 (CDH6) gene was found to be frequently overexpressed in ovarian and renal cancers, while featuring a lineage-restricted normal tissue expression pattern. We hypothesized that based onExpand